| NCT ID | NCT06551090 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | Anxiety |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-07-23 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-07-23 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to look at how signals in the brain, body, and behavior relate to anxiety and memory function. This project seeks to develop the CAMERA (Context-Aware Multimodal Ecological Research and Assessment) platform, a state-of-the-art open multimodal hardware/software system for measuring human brain-behavior relationships. The R61 portion of the project is designed to develop the CAMERA platform, which will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy, as well as to build CAMERA's passive data framework and active data framework.
Eligibility Criteria
Inclusion Criteria: * Patients must have known or suspected Temporal Lobe Epilepsy. * Native or proficient in speaking English or Spanish. * Stereoelectroencephalography (sEEG) cases: The implant plan must include hippocampal head, body, and tail electrodes either unilaterally or bilaterally. * 7th grade reading level (minimum level considered literate for adults) Exclusion Criteria: * Hearing impaired (i.e., not corrected with a hearing aid) * Unable to read the newspaper at arm's length with corrective lenses. * Objective intellectual impairment (estimated IQ \< 70) * Any history of Electroconvulsive Therapy or psychosis (except postictal psychosis for patients) * Psychotic disorder (lifetime) * Current Anxiety disorder, Major Depressive Disorder, or Bipolar Disorder * Neurodegenerative diseases, presence of widespread brain lesions, language problems (other than naming difficulty) * Medical conditions that could potentially affect cognitive performance (e.g., human immunodeficiency virus (HIV) infection, cancer with metastatic potential). * Acute renal failure or end-stage renal disease
Contact & Investigator
Joshua Jacobs, PhD
STUDY DIRECTOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06551090 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06551090 currently recruiting?
Yes, NCT06551090 is actively recruiting participants. Contact the research team at bey2103@cumc.columbia.edu for enrollment information.
Where is the NCT06551090 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06551090 clinical trial?
NCT06551090 is sponsored by Columbia University. The principal investigator is Joshua Jacobs, PhD at University of Chicago. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.